Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms

Authors

  • Eva Tiensuu Janson Department of Medical Sciences, Uppsala University, Uppsala, Sweden
  • Halfdan Sorbye Department of Oncology, Haukeland University Hospital, Bergen, Norway
  • Staffan Welin Department of Medical Sciences, Uppsala University, Uppsala, Sweden
  • Birgitte Federspiel Department of Pathology, Rigshospitalet, Faculty of Health Science, University of Copenhagen, Copenhagen, Denmark
  • Henning Grønbæk Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark
  • Per Hellman Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
  • Morten Ladekarl Department of Oncology, Aarhus University Hospital, Aarhus, Denmark
  • Seppo W. Langer Department of Oncology, Rigshospitalet, Faculty of Health Science, University of Copenhagen, Copenhagen, Denmark
  • Jann Mortensen Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet, Faculty of Health Sciences, University of Copenhagen, Denmark
  • Camilla Schalin-Jäntti Division of Endocrinology, Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland
  • Anders Sundin Department of Radiology, Oncology and Radiation Sciences, Uppsala University, Uppsala, Sweden
  • Anna Sundlöv Department of Oncology, Skåne University Hospital, Lund, Sweden
  • Espen Thiis-Evensen Department for Organ Transplantation, Oslo University Hospital, Rikshospitalet, Oslo Norway
  • Ulrich Knigge Departments of Surgery C and Endocrinology PE, Rigshospitalet, Faculty of Health Science, University of Copenhagen, Copenhagen, Denmark

DOI:

https://doi.org/10.3109/0284186X.2014.941999

Abstract

Background. The diagnostic work-up and treatment of patients with neuroendocrine neoplasms (NENs) has undergone major recent advances and new methods are currently introduced into the clinic. An update of the WHO classification has resulted in a new nomenclature dividing NENs into neuroendocrine tumours (NETs) including G1 (Ki67 index ≤ 2%) and G2 (Ki67 index 3–20%) tumours and neuroendocrine carcinomas (NECs) with Ki67 index > 20%, G3. Aim. These Nordic guidelines summarise the Nordic Neuroendocrine Tumour Group's current view on how to diagnose and treat NEN-patients and are meant to be useful in the daily practice for clinicians handling these patients.

Downloads

Download data is not yet available.

Downloads

Published

2014-10-01

How to Cite

Tiensuu Janson, E., Sorbye, H., Welin, S., Federspiel, B., Grønbæk, H., Hellman, P., … Knigge, U. (2014). Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta Oncologica, 53(10), 1284–1297. https://doi.org/10.3109/0284186X.2014.941999

Issue

Vol. 53 No. 10 (2014): Acta Oncologica

Section

Articles